This 10 week study followed by a 20 week open label extension study is evaluating the efficacy of an new investigational medication (BMS-95456) compared to placebo to reduce the pain in patients with PHN.

Major Inclusion/Exclusion:

• Ages 18-85
• Persistent PHN pain for a minimum of 6 months following the onset of a herpes zoster skin rash (shingles).
• Must not have any other neuropathic pain.